000199016 001__ 199016
000199016 005__ 20181203023510.0
000199016 0247_ $$2doi$$a10.1128/Aac.00037-14
000199016 022__ $$a0066-4804
000199016 02470 $$2ISI$$a000334364300067
000199016 037__ $$aARTICLE
000199016 245__ $$aCross-Resistance between Clofazimine and Bedaquiline through Upregulation of MmpL5 in Mycobacterium tuberculosis
000199016 260__ $$bAmer Soc Microbiology$$c2014$$aWashington
000199016 269__ $$a2014
000199016 300__ $$a3
000199016 336__ $$aJournal Articles
000199016 520__ $$aThe antileprosy drug clofazimine is also of interest for the treatment of multidrug-resistant tuberculosis. To understand possible resistance mechanisms, clofazimine-resistant Mycobacterium tuberculosis mutants were isolated in vitro, and, unexpectedly, found to be cross-resistant to bedaquiline. Mutations in the transcriptional regulator Rv0678, with concomitant upregulation of the multisubstrate efflux pump, MmpL5, accounted for this cross-resistance. Mutation in Rv0678 should therefore be considered a confounding factor for the treatment of tuberculosis with clofazimine or bedaquiline.
000199016 700__ $$0244368$$g183097$$aHartkoorn, Ruben C.
000199016 700__ $$0244370$$g181909$$aUplekar, Swapna
000199016 700__ $$aCole, Stewart T.$$g177247$$0243892
000199016 773__ $$j58$$tAntimicrobial Agents And Chemotherapy$$k5$$q2979-2981
000199016 909C0 $$xU11742$$0252302$$pUPCOL
000199016 909CO $$pSV$$particle$$ooai:infoscience.tind.io:199016
000199016 917Z8 $$x164606
000199016 937__ $$aEPFL-ARTICLE-199016
000199016 973__ $$rREVIEWED$$sPUBLISHED$$aEPFL
000199016 980__ $$aARTICLE